Novavax and Government of Canada Finalize Advance Purchase Agreement for COVID-19 Vaccine Canadian government commits to purchase 52 million doses with option for additional 24 million of Novavax candidate vaccine, [….]
$7.50 per share
Gaithersburg biotech NexImmune starts the new year by filing for an initial public offering. Here are the details.
/PRNewswire/ — Slate Bio, Inc., announced today the closing of a $1.75 million venture financing. Epidarex Capital led the investment round wit
Theradaptive, Inc. received a $6.2 million infusion of cash from a Series A funding round that will be used to drive the company’s lead biologic asset, AMP2, into clinical trials next year.
FREDERICK, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) — RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks, highly engineered media and hMSC bioprocess systems, today announces the signing of a strategic collaboration with Sartorius, a leading international partner of life science research and the biopharmaceutical industry. The collaboration aims to…
Novavax tapped Baxter BioPharma Solutions to support commercial-scale vaccine manufacturing at its facility in Halle, Germany. Once manufacturing work kicks off, Baxter will be on deck to crank out supplies for the European and U.K. markets, the companies said.
Delfi Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early Detection Liquid Biopsy for Multiple Cancers
Novel liquid biopsy technology combines machine learning and low-cost cell free DNA genome-wide fragmentation profiles BALTIMORE, January 12, 2021 /PRNewsire/ — Delfi Diagnostics, Inc., a pioneering developer of a new class [….]
Veralox Therapeutics Announces IND Submission for VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced it submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a Phase 1 clinical trial of VLX-1005, a first-in-class small molecule inhibitor of 12-Lipoxygenase in development for the treatment of heparin-induced thrombocytopenia (HIT).
Rockville’s Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform
– Round co-led by Apeiron Investment Group and Catalio Capital Management – Proceeds support advancement of lead product candidate and next-generation platform for personalized yet off-the-shelf cancer immunotherapies BOSTON & [….]